Summary - MESO - NASDAQ - Weiss Ratings

E

Mesoblast Limited MESO

$18.38 -$0.39-2.08% NASDAQ

Recommendation

Prev Close

Volume

Avg Vol (90D)

Market Cap

Dividend & Yield

--

52-Week Range

$9.61 - $21.50

P/E (TTM)

--

EPS (TTM)

My Lists My Alerts

Access our Premium Ratings

Get Access

Rating

Reward

Risk

Rating Factors

Growth Index

Efficiency Index

Solvency Index

Total Return Index

Volatility Index

Dividend Index

Headlines

Mesoblast (MESO, $18.77) price moved above its 50-day Moving Average on January 22, 2026

1/23/2026 - Tickeron - Stocks

Mesoblast (MESO, $16.83) price exceeded its 50-day Moving Average on January 20, 2026

1/21/2026 - Tickeron - Technical Analysis

Mesoblast (NASDAQ:MESO) Shares Cross Below 50 Day Moving Average - Here's What Happened

1/21/2026 - MarketBeat

FDA Signals Support For Mesoblast's Cell Therapy For Chronic Back Pain

1/20/2026 - Benzinga

FDA Feedback Boosts Mesoblast's (MESO) Cell Therapy Prospects

1/19/2026 - GuruFocus

Mesoblast received FDA feedback on potential BLA for rexlemestrocel-L

1/19/2026 - TipRanks Financial Blog

Mesoblast received FDA feedback on potential BLA for rexlemestrocel-L

1/19/2026 - The Fly

FDA Feedback Boosts Mesoblast's Rexlemestrocel L Bid in Chronic Low Back Pain

1/19/2026 - TipRanks Financial Blog

FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy

1/19/2026 - Globe Newswire

Mesoblast (NASDAQ:MESO) Stock Price Down 5.5% - Here's What Happened

1/13/2026 - MarketBeat

Mesoblast (MESO, $18.67) Stochastic Oscillator left the overbought zone on January 12, 2026

1/13/2026 - Tickeron - Technical Analysis

Mesoblast (MESO, $18.67) RSI Indicator left the overbought zone on January 12, 2026

1/13/2026 - Tickeron - Technical Analysis

Mesoblast (MESO, $18.67) entered Downtrend as Momentum indicator drops below 0 level on Jan 12, 2026

1/13/2026 - Tickeron - Technical Analysis

Mesoblast (MESO, $18.67) Moving Average Convergence Divergence (MACD) Histogram turned negative on January 12, 2026

1/13/2026 - Tickeron - Technical Analysis

Mesoblast Director Eric Rose Increases Shareholding Through Option Exercise

1/13/2026 - TipRanks Financial Blog

Mesoblast (NASDAQ:MESO) Shares Gap Down - Time to Sell?

1/12/2026 - MarketBeat

Mesoblast Director Lyn Cobley Increases On-Market Shareholding

1/11/2026 - TipRanks Financial Blog

Mesoblast (MESO, $20.96) Moving Average Convergence Divergence (MACD) Histogram turned positive on January 9, 2026

1/10/2026 - Tickeron - Stocks

Mesoblast (MESO, $20.96) RSI Indicator left the overbought zone on January 09, 2026

1/10/2026 - Tickeron - Stocks

Mesoblast (MESO, $20.96) price may drop as it broke higher Bollinger Band on Jan 09, 2026

1/10/2026 - Tickeron - Stocks

Mesoblast (MESO) Sees Revenue Surge and Secures $125M Loan

1/10/2026 - GuruFocus

Mesoblast rises as Ryoncil sales climb 60% in December quarter

1/9/2026 - Seeking Alpha - Healthcare

Mesoblast rises as Ryoncil sales climb 60% in December quarter

1/9/2026 - SeekingAlpha.com: All News

Mesoblast (NASDAQ:MESO) Sets New 52-Week High - Here's Why

1/9/2026 - MarketBeat

Ryoncil Sales Increase 60% in December Quarter to US$35.1M

1/8/2026 - Globe Newswire

Income Statement

Total Revenue (TTM)

EBITDA (TTM)

EBIT (TTM)

Net Income (TTM)

Balance Sheet

Total Assets (Q)

Total Debt (Q)

Total Liabilities (Q)

Book Value Per Share (Q)

Cash Flow

Cash from Operations (TTM)

Cash from Investing (TTM)

Cash from Financing (TTM)

Net Change in Cash (TTM)

Filings

Filing Date

Thursday, August 28, 2025

Period Date

Monday, June 30, 2025

Next Filing

Week of Feb 23 and 27 (est)

Price History

Loading...

Beta

7-Day Total Return

30-Day Total Return

60-Day Total Return

90-Day Total Return

Year to Date Total Return

1-Year Total Return

2-Year Total Return

3-Year Total Return

5-Year Total Return

52-week Low

Apr 07, 2025 - $9.61

52-week High

Jan 09, 2026 - $21.50

Valuation

Market Cap

$2.33B - Mid Cap

Enterprise Value

Price/Sales (TTM)

Price/Book (Q)

Dividends and Shares

Shares Outstanding

Dividend Per Share (Most Recent)

--

Dividend Per Share (TTM)

--

Corporate Info

Website

www.mesoblast.com

Phone Number

61 3 9639 6036

Address

55 Collins Street
Melbourne, VIC 3000

Country

Year Founded

Business Description

Sector

Industry

Pharmaceuticals, Biotechnology and Life Sciences

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s... more